J
Justin Saco
Researcher at University of California, Los Angeles
Publications - 14
Citations - 4052
Justin Saco is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: T-cell receptor & T cell. The author has an hindex of 5, co-authored 10 publications receiving 2861 citations.
Papers
More filters
Journal ArticleDOI
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Jesse M. Zaretsky,Angel Garcia-Diaz,Daniel Sanghoon Shin,Helena Escuin-Ordinas,Willy Hugo,Siwen Hu-Lieskovan,Davis Y. Torrejon,Gabriel Abril-Rodriguez,Salemiz Sandoval,Lucas Barthly,Justin Saco,Blanca Homet Moreno,Riccardo Mezzadra,Bartosz Chmielowski,Kathleen Ruchalski,I. Peter Shintaku,Phillip J. Sanchez,Cristina Puig-Saus,Grace Cherry,Elizabeth Seja,Xiangju Kong,Jia Pang,Beata Berent-Maoz,Begoña Comin-Anduix,Thomas G. Graeber,Paul C. Tumeh,Ton N. Schumacher,Roger S. Lo,Antoni Ribas +28 more
TL;DR: Acquired resistance to PD-1 blockade immunotherapy in patients with melanoma was associated with defects in the pathways involved in interferon-receptor signaling and in antigen presentation.
Journal ArticleDOI
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.
Angel Garcia-Diaz,Daniel Sanghoon Shin,Blanca Homet Moreno,Justin Saco,Helena Escuin-Ordinas,Gabriel Abril Rodriguez,Jesse M. Zaretsky,Lu Sun,Willy Hugo,Xiaoyan Wang,Giulia Parisi,Cristina Puig Saus,Davis Y. Torrejon,Thomas G. Graeber,Begonya Comin-Anduix,Siwen Hu-Lieskovan,Robert Damoiseaux,Roger S. Lo,Antoni Ribas +18 more
TL;DR: Analysis of biopsy specimens from patients with melanoma confirmed interferon signature enrichment and upregulation of gene targets for STAT1/STAT2/STAT3 and IRF1 in anti-PD-1-responding tumors.
Journal ArticleDOI
Reprogramming human T cell function and specificity with non-viral genome targeting
Theodore L. Roth,Cristina Puig-Saus,Ruby Yu,Ruby Yu,Eric Shifrut,Eric Shifrut,Julia Carnevale,P. Jonathan Li,P. Jonathan Li,Joseph Hiatt,Justin Saco,Paige Krystofinski,Han Li,Victoria Tobin,Victoria Tobin,David N. Nguyen,David N. Nguyen,Michael R. Lee,Amy L. Putnam,Andrea L. Ferris,Jeff W. Chen,Jean Nicolas Schickel,Laurence Pellerin,David Carmody,Gorka Alkorta-Aranburu,Daniela del Gaudio,Hiroyuki Matsumoto,Montse Morell,Ying Mao,Min Cho,Rolen M. Quadros,Channabasavaiah B. Gurumurthy,Baz Smith,Michael Haugwitz,Stephen H. Hughes,Jonathan S. Weissman,Kathrin Schumann,Kathrin Schumann,Jonathan H. Esensten,Andrew P. May,Alan Ashworth,Gary M. Kupfer,Siri Atma W. Greeley,Rosa Bacchetta,Eric Meffre,Maria Grazia Roncarolo,Neil Romberg,Neil Romberg,Kevan C. Herold,Antoni Ribas,Manuel D. Leonetti,Alexander Marson +51 more
TL;DR: A non-viral strategy to introduce large DNA sequences into T cells enables the correction of a pathogenic mutation that causes autoimmunity, and the replacement of an endogenous T-cell receptor with an engineered receptor that can recognize cancer antigens.
Journal ArticleDOI
Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist
Giulia Parisi,Justin Saco,Felix B. Salazar,Jennifer Tsoi,Paige Krystofinski,Cristina Puig-Saus,Ruixue Zhang,Jing Zhou,Gardenia Cheung-Lau,Alejandro J. Garcia,Catherine S. Grasso,Richard Tavaré,Siwen Hu-Lieskovan,Sean Mackay,Jonathan Zalevsky,Chantale Bernatchez,Adi Diab,Anna M. Wu,Anna M. Wu,Begoña Comin-Anduix,Deborah H. Charych,Antoni Ribas +21 more
TL;DR: NKTR-214 may have the potential to improve the antitumor activity of ACT in humans through increased in vivo expansion and polyfunctionality of the adoptively transferred T cells.
Posted ContentDOI
Reprogramming human T cell function and specificity with non-viral genome targeting
Theodore L. Roth,Cristina Puig-Saus,Ruby Yu,Eric Shifrut,Julia Carnevale,Joseph Hiatt,Justin Saco,Han Li,Han Li,Jonathan Li,Victoria Tobin,David N. Nguyen,Andrea M. Ferris,Jeff W. Chen,Jean-Nicolas Schickel,Laurence Pellerin,David Carmody,Gorka Alkorta-Aranburu,Daniela del Gaudio,Hiroyuki Matsumoto,Montse Morell,Ying Mao,Rolen M. Quadros,Channabasavaiah B. Gurumurthy,Baz Smith,Michael Haugwitz,Stephen H. Hughes,Jonathan S. Weissman,Jonathan S. Weissman,Kathrin Schumann,Andrew P. May,Alan Ashworth,Gary M. Kupfer,Siri Atma W. Greeley,Rosa Bacchetta,Eric Meffre,Maria Grazia Roncarolo,Neil Romberg,Kevan C. Herold,Antoni Ribas,Manuel D. Leonetti,Manuel D. Leonetti,Alexander Marson +42 more
TL;DR: A non-viral, CRISPR-Cas9 genome targeting system that permits the rapid and efficient insertion of individual or multiplexed large DNA sequences at specific sites in the genomes of primary human T cells while preserving cell viability and function is developed.